ArticleAnnals of surgical oncology2026
A Novel Model for Muscle-Invasive Bladder Cancer Diagnosis Using Contrast-Enhanced Ultrasound.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
Abstract
backgroundAccurate preoperative identification of muscle-invasive bladder cancer (MIBC) is critical for clinical decision-making but remains challenging. In this study, we aimed to develop and validate a novel predictive model that integrates contrast-enhanced ultrasound (CEUS) radiomics features with the Vesical Imaging Reporting and Data System (VI-RADS) score to improve the preoperative discrimination of MIBC.
methodsIn this retrospective, single-center study, we enrolled 116 consecutive patients with pathologically confirmed bladder tumor who underwent pre-operative CEUS between May 2015 and October 2024. Patients were randomly allocated to training and validation cohorts in a 7:3 ratio. The CEUS frame at peak tumor enhancement was selected for analysis. Tumors were manually segmented on the largest cross-sectional plane using 3D-Slicer to generate regions of interest. Radiomic features were extracted using PyRadiomics. After sequential feature reduction and model selection, radiomic predictors were integrated with clinically significant variables to construct a combined model.
resultsThree CEUS radiomic features were identified as relevant to MIBC. Among clinical variables, the VI-RADS score (P=0.04, odds ratio 1.89) was independently associated with MIBC. Of the five evaluated classifiers, XGBoost achieved the best performance for both the radiomic (area under the curve 0.86) and the combined (area under the curve 0.96) models. Finally, SHapley Additive exPlanations analysis was performed to interpret the model, and calibration curves and decision curve analysis were employed to evaluate its accuracy and clinical utility.
conclusionThis study developed and conducted preliminary validation of a model integrating CEUS radiomics and the VI-RADS score, demonstrating its feasibility and potential for preoperative MIBC prediction.
Indexed as
Identifiers
41637022What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.